IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best medical technology stocks to invest in. On February 3, BTIG lowered its price target on IDEXX Laboratories Inc. (NASDAQ:IDXX) to $800 from $830 and maintained a Buy rating. The firm cited concerns about IDEXX’s 2026 guidance despite robust Q4 2025 earnings performance.
IDEXX reported strong fourth-quarter results, with revenue of $1.09 billion, up 14% from last year and above analyst expectations of $1.072 billion. Earnings per share rose 18% to $3.08, beating the Street’s $2.93 estimate. The company remains highly profitable, with a 61.7% gross margin and a return on equity of 65% over the past 12 months.
The companion animal business, IDEXX’s core segment, grew 15% to $998 million, driven by strong instrument revenue of $58 million, up 76% year-over-year. Growth was supported by 1,940 InVueDx system placements, as well as strong demand for Catalyst and SediVue products. This continues IDEXX’s long-term trend of about 10% annual revenue growth and aligns with management’s strategy of share buybacks to boost shareholder value.
For 2026, IDEXX expects revenue of $4.63–$4.72 billion and EPS of $14.29–$14.80, with operating margins slightly improving to 32%–32.5%. BTIG noted a 200-basis-point drag from fewer pet visits, mainly from lower-income owners, but expects 4% price growth globally. The company also plans around 5,500 new InVueDx system placements next year, compared with 6,400 in 2025, to help offset these headwinds.
IDEXX Laboratories Inc. (NASDAQ:IDXX) develops, manufactures, and distributes diagnostic and information technology products for veterinary, livestock, poultry, dairy, and water testing markets. Its offerings include point-of-care diagnostic instruments, rapid assay test kits, veterinary reference laboratory services, and microbiological contaminant testing systems.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nonfarm Payrolls Significantly Below Expectations! U.S. Added 29,000 Jobs in August vs. Expected 90,000; U.S. Treasury Yields Fall, U.S. Stock Futures Rise
In September, non-farm employment in the United States increased by only 29,000, far below the expected 90,000, and the unemployment rate rose slightly from 4.1% in August to 4.2%. After the data release, the probability of a Federal Reserve rate hike in October dropped from 22% to 17%, and the expected cumulative rate hike for the remaining two meetings of the year decreased to about 21 basis points. The yield on two-year U.S. Treasury bonds dropped 10 basis points in a single day, while S&P 500 futures rose by 0.8%. Economists attribute the unusual weakness to distortions from seasonal adjustment factors rather than a substantive shift in the labor market.
Crypto prices
More
